TIDMSN.
RNS Number : 1376Z
Smith & Nephew Plc
10 January 2024
Smith+Nephew completes acquisition of novel cartilage
regeneration technology for sports medicine knee repair
10 January 2024
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology
company, announces that it has completed the acquisition of
CartiHeal, developer of
Agili-C, a novel sports medicine technology for cartilage
regeneration in the knee.
Agili-C is an off-the-shelf one-step treatment for osteochondral
(bone and cartilage) lesions with a broader indication than
existing treatments. It is indicated to treat a wide patient
population, including those with lesions in knees with mild to
moderate osteoarthritis , a previously unaddressed condition, as
well as the approximately 700,000 patients(1) that receive
cartilage repair annually in the US.
"With its proven superiority(2) to current standard of care,
Agili-C has the potential to transform cartilage repair outcomes,"
said Scott Schaffner, President Sports Medicine, Smith+Nephew. "Our
expertise in regenerative therapy and leadership in knee repair
gives me great confidence that this will be a significant value
creator for Smith+Nephew."
Smith+Nephew paid $180 million on completion, with up to a
further $150 million contingent on future financial performance, as
previously disclosed.
Enquiries
Investors / Analysts
Andrew Swift
Smith+Nephew +44 (0) 1923 477433
Media
Charles Reynolds
Smith+Nephew +44 (0) 1923 477314
Susan Gilchrist / Ayesha Bharmal
Brunswick +44 (0) 20 7404 5959
References
1. Medtech 360, Sports Medicine Devices, Market Analysis, US,
2018, Millennium Research Group, Inc.
2. The U.S. Food and Drug Administration (FDA) granted Agili-C
Breakthrough Device designation status in 2020 and Premarket
Approval (PMA) in March 2022. PMA approval was granted based on the
results of a two-year randomised controlled trial (N=251) that
confirmed superiority of Agili-C over current standard of care -
microfracture and debridement for the treatment of knee joint
surface lesions, chondral and osteochondral defects. Study
inclusion criteria included patients with mild and moderate
osteoarthritis.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that
exists to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 19,000 employees deliver this mission every
day, making a difference to patients' lives through the excellence
of our product portfolio, and the invention and application of new
technologies across our three global business units of
Orthopaedics, Advanced Wound Management and Sports Medicine &
ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.2 billion in 2022.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on X , LinkedIn , Instagram or
Facebook .
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading profit margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of Covid, such as the depth and longevity of
its impact, government actions and other restrictive measures taken
in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
Covid; economic and financial conditions in the markets we serve,
especially those affecting healthcare providers, payers and
customers (including, without limitation, as a result of Covid);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal and financial compliance
risks and related investigative, remedial or enforcement actions;
disruption to our supply chain or operations or those of our
suppliers (including, without limitation, as a result of Covid);
competition for qualified personnel; strategic actions, including
acquisitions and disposals, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments;
relationships with healthcare professionals; reliance on
information technology and cybersecurity; disruptions due to
natural disasters, weather and climate change related events;
changes in customer and other stakeholder sustainability
expectations; changes in taxation regulations; effects of foreign
exchange volatility; and numerous other matters that affect us or
our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, which is available on the SEC's website at www. sec.gov, for
a discussion of certain of these factors. Any forward-looking
statement is based on information available to Smith+Nephew as of
the date of the statement. All written or oral forward-looking
statements attributable to Smith+Nephew are qualified by this
caution. Smith+Nephew does not undertake any obligation to update
or revise any forward-looking statement to reflect any change in
circumstances or in Smith+Nephew's expectations.
Trademark of Smith+Nephew. Certain marks registered in US Patent
and Trademark Office.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACQEASFNEAFLEFA
(END) Dow Jones Newswires
January 10, 2024 02:00 ET (07:00 GMT)
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Mag 2023 a Mag 2024